Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
20,317 results
- Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years): Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years): primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to
- Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR): Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02445963).
- Safety and Immunogenicity of CJCV2 With and Without ALFQ: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of CJCV2 With and Without ALFQ: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05500417).
- Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®: primary endpoint results, effect estimate with…
- Safety and Immunogenicity of Different Schedules of Takeda’s Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Immunogenicity of GSK Biologicals’ HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old: primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety and Immunogenicity of GSK’s Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib Vaccine (GSK217744): Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years: primary endpoint results, effect estimate with…
- Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.: primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above: primary endpoint…
- Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01147068).
- Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003): Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine: primary endpoint results, effect…
- Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003): Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age: primary endpoint results, effect estimate with confidence…
- Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age: primary endpoint results, effect estimate…
- Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7): Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10): Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea: primary endpoint results, effect estimate with confidence…
- Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals’ 10-valent Pneumococcal Conjugate Vaccine.: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Immunogenicity Study of GSK Biologicals’ Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years: primary endpoint results, effect estimate with…
- Safety and Immunogenicity Study of Na-GST-1 With or Without CpG: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of Na-GST-1 With or Without CpG: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02143518).
- Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04074928).
- Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Immunogenicity Study of Traveler’s Diarrhea Vaccine Patch: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01067781).